Target discovery
Data driven approach to
target discovery
Discovery of new therapeutic targets is essential to the development of new medicine. The identification of key disease-modifying targets lays the foundation for any successful drug discovery.
Our streaMLine preDict platform has a scientific and data driven approach and is designed to identify novel targets that are drugable, clinically efficacious and safe.
Our in-house capabilities enable rapid validation of targets in clinical translatable in vivo models.
Related Links:
Target discovery offerings
All capabilities in-house
- Cross-disciplinary teams ensure efficient study conduction.
- Efficient and smooth data-transfer.
Database - preclinical and clinical samples
- Rodent – and human data compiled in one searchable format.
- Opportunity to combine/merge with own or publicly available data.
Advanced Computational Biology
- Customised biological focus and data filtration.
- Easily accessible platform for data handling and visualisation.
Validation in clinically translatable in vivo models
- Large array of rodent disease models.
- Access to sophisticated surgical techniques.
- Real-time monitoring of individual animals.
- In-house facilities ensuring rapid execution.
Agile project management
- Experienced project managers with target discovery expertise.
- PhD research scientist with in-depth knowledge on disease aetiology.
- Focus on lean experimental setup for your scientific question.
streaMLine for target identification and validation
Our target discovery platform, streaMLine preDict, combines vast amounts of preclinical data to identify novel druggable targets. We apply advanced analytical methods such as RNAseq, scRNAseq, AI assisted histopathology and various biochemical assays on samples from Gubra´s industry golden standard rodent disease models.
Our preDict algorithm identifies and ranks targets based on unique in-house developed algorithms. Evaluation of clinical data is included to ensure human translatability of targets.
Explore some of our target discovery projects
See examples on how accumulated data from hundreds of preclinical and clinical samples are used to preDict future drug targets.
Publications
- Gut Mucosal Gene Expression and Metabolic Changes After Roux‐en‐Y Gastric Bypass Surgery
- The preprohormone expression profile of enteroendocrine cells following Roux-en-Y gastric bypass in rats
- Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control
Why choose Gubra?
- Proven track record with identification of new disease targets and new peptide drugs. The most advanced are currently in clinical development with pharma partner.
- All projects are led by professional project leaders with strong scientific backgrounds and project management experience.
- All data are generated in-house to ensure high data quality, integrity, speed and flexibility.
- Our in-house in vivo facility is AAALAC accreditated.
Get in touch
Please get in touch if you are interested in discussing how to get started with your study.
Jacob Jelsing
Co-founder, Vice Chairman of the Board
jacob@gubra.dk
+45 2382 9493
